Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

ABSTRACT:

Background

The frequency with which targeted tumor sequencing results will lead to implemented change in care is unclear. Prospective assessment of the feasibility and limitations of using genomic sequencing is critically important.

Methods

A prospective clinical study was conducted on 100 patients with diverse-histology, rare, or poor-prognosis cancers to evaluate the clinical actionability of a Clinical Laboratory Improvement Amendments (CLIA)-certified, comprehensive genomic profiling assay (FoundationOne), using formalin-fixed, paraffin-embedded tumors. The primary objectives were to assess utility, feasibility, and limitations of genomic sequencing for genomically guided therapy or other clinical purpose in the setting of a multidisciplinary molecular tumor board.

Re

SUBMITTER: Hirshfield KM 

PROVIDER: S-EPMC5189630 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature